Effects of risedronate on metabolic bone disease in patients with type 1 diabetes and osteoporosis
- María del Mar Campos Pastor
- Juan de Dios Luna del Castillo
- Fernando Escobar Jiménez
- F.J. Gómez Jiménez
- M.D. Serrano Pardo
- P. López-Ibarra
ISSN: 1132-8460
Any de publicació: 2008
Volum: 17
Número: 4
Pàgines: 66-70
Tipus: Article
Altres publicacions en: Revista Española de Enfermedades Metabólicas Oseas
Resum
To assess the effect of a antiresorptive on bone mass and remodeling markers in patients with type 1 diabetes mellitus (DM-1) and osteoporosis (OP). Study included 52 patients with DM-1 of 21-36 years duration and OP or osteopenia, aged 29-69 years. OP patients received 30 mg/week risedronate (n=35) and calcium+vitamin D; osteopenic patients and risedronate refusers (n=17) received only calcium+vitamin D. At 12 months, the risedronate group showed significant improvements in tartrate resistant acid phosphatase (p<0.0001), osteocalcin (BGP) (p<0.0001), bone alkaline phosphatase (BAP) (p<0.0001), and hemoglobin A1c (HbA1c) (p<0.0001); bone mineral density (BMD) was increased at 6 and 12 months versus baseline in lumbar spine (LS) (p<0.0001) and femoral neck (FN) (p<0.0001). At 12 months, the conventional group showed a significant improvement in HbA1c (p<0.012) and reduction in BGP (p<0.03) and BAP (p<0.0001). The conventional treatment group showed no significant changes in BMD at LS and FN during the 12-month period. Risedronate treatment improves BMD in long-term DM-1 patients.